The end of triglycerides in cardiovascular risk assessment?: Rumours of death are greatly exaggerated

BMJ

Volumn 317, Issue 7158, 1998, Pages 553-554

  Packard, Chris J ^a   Petrie, John R ^b   Satta, Naveed ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ATHEROGENESIS; CARDIOVASCULAR RISK; EDITORIAL; HUMAN; MASS SCREENING; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; RISK ASSESSMENT; TRIGLYCERIDES;

EID: 0032578328     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.317.7158.553     Document Type: Editorial

References (12)

1. Garber AM, Avins AL. Triglyceride concentration andc oronary heart disease. Not yet proved as a screening rest. BMJ 1994; 309: 2–3
2. Assmann G, Schulte H. Relationship of high densityl ipoprotein cholesterol and triglycerides to incidence of atheroscleroticc oronary artery disease (the PROCAM experience). Am J Cardiol 1992; 70: 733–741
3. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridaemia and elevated lipoprotein (a) are risk factors for majorc oronary events in middle-aged men. Am J Cardiol 1996; 77: 1179–1184
4. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks F, et al. A prospective study of triglyceride level, low-densityl ipoprotein particle diameter and risk of myocardial infarction. JAMA 1996; 276: 882–888
5. Hokanson JE, Austin MA. Plasma triglyceride level is ar isk factor for cardiovascular disease independent of high-density lipoproteinc holesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213–219
6. Ebenbichler CF, Kirchmair R, Egger C, Patsch JR. Post-prandial state and atherosclerosis. Curr Opin Lipidol 1995; 6: 286–290
7. Sattar N, Petrie JR, Jaap AJ. The atherogenicl ipoprotein profile and vascular endothelial dysfunction. Atherosclerosis (in press).
8. Superko HR. What can we learn about dense low-densityl ipoprotein particles from clinical trials. Curr Opin Lipidol 1996; 7: 363–368
9. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: does thec lock for coronary heart disease start ticking before the onset of clinicald iabetes? JAMA 1990; 263: 2893–2898
10. MAAS Investigators. Effect of simvastatin on coronarya theroma: the multicentre anti-atheroma study (MAAS). Lancet 1994; 344: 633–638
11. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progressiono f coronary heart disease in young male postinfarction patients. Lancet 1996; 347: 849–8531001-9.
12. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, et al. Joint effects of serum triglyceride andl ow-density lipoprotein cholesterol and high density cholesterolc oncentrations on coronary heart disease risk in the Helsinki heart study:i mplications for treatment. Circulation 1992; 85: 37–45